Santen Pharmaceutical Co., Ltd specializes in the global research and development, manufacturing, and sales and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people worldwide.

Santen Pharmaceutical Co., Ltd

Cloudflare JS

CDN JS

Network Solutions DNS

Network Solutions

President at Santen Ventures, Inc.

Frank Chen

Frank Lee Chen

President of Europe, Middle East & Africa. Corporate Officer

Luis Iglesias

Vice President, Global Head Data Sciences & Biometrics, Santen

Kay Tatsuoka

Managing Director (Santen Oy & SantenPharma AB) / Vice President Central Region EMEA

Lasse Kovalainen

VP Regulatory

Mark Mannebach

Marketing and Product

Peter Sallstig

VP, Head of Global Compliance at Santen Ltd.

Robert Van Leer

Vice President Marketing

Santos Torres

VP, Modality Innovation

Sri Mudumba

Masahiro Inoue

Chief Administrative Officer

Akira Kurokawa

Usha Srinivasan

Senior Director, Global Regulatory Affairs

Frank Binder

Global Head Supply Chain Management

Mika Masunari

Vice President, Legal and Compliance

Naj Sharif

Executive Director, and Head Global Biomedical Sciences/ Alliances & External Research

Najam Sharif

VP, Global Biomedical Sciences & Strategy

Kenkichi Taguchi

Founder

InnFocus is a biomaterials company developing products for the ophthalmology sector.

RetroSense Therapeutics is a biotechnology company developing gene therapy for vision restoration.

Clearside BioMedical is an ophthalmic company that specializes in the research, development, and commercialization of therapeutic products.

Health Care Acquired Companies With More Than $100M in Revenue

Investors Active in Charlottesville, Virginia

Auriga Partners Portfolio Companies

United States Acquired Companies With More Than $500 in Revenue

Santen specializes in the research, development, marketing, and sales of innovative eye care products and services that enable optimal sight. They help physicians address the complex clinical challenges in vision care with novel solutions for glaucoma, retinal diseases, and other eye conditions.

Post-IPO Equity - Santen Pharmaceutical

Emeryville

California

United States

North America

Santen Pharmaceutical

Santen and U.S. Ophthalmic Company Eyevance Enter into Share Purchase Agreement

jCyte Inc. Enters into Ex-US Licensing and Commercialization Agreement for jCell Therapy with Global Ophthalmology Leader Santen Pharmaceutical

Verily plans digital eye care joint venture with Japan's Santen Pharma

Glaukos, Stanten ink U.S. MicroShunt distro deal

Nikkei snaps 3-day winning streak, exporters retreat

Santen Hosts Event to Raise Public Awareness of Importance of Continued Glaucoma Treatment Prior to Sponsoring World Glaucoma Week in March

Santen Presents Phase I/II Data on DE-122 (Carotuximab) in Patients with Refractory Wet Age-Related Macular Degeneration

HTML5

Microsoft Outlook

jQuery

Office 365

Google Tag Manager

Google Fonts

Bootstrap

Google Analytics

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Santen Pharmaceutical Co., Ltd.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 29, 2024 12:49 PM	6214938b
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 29, 2024 12:49 PM	3459f509
crunchbase trigger	general	Oct 29, 2024 5:10 PM	546dc856
crunchbase profile	general	Oct 30, 2024 12:03 PM	eeca87c8
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	07555a49
peers	general	Sep 29, 2024 12:49 PM	da09cca8
news basic	general	Sep 29, 2024 12:49 PM	10e2a9f0
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:SANTEN

Santen Pharmaceutical Co., Ltd

Last Close

1,670.50

25/11 06:45

Market Cap

650.87B

Beta: -

Volume Today

1.70M

Avg: -